Alembic Pharmaceuticals has posted net profit growth of 16.3 per cent during the third quarter ended December 2012 to Rs.44.23 crore from Rs.38.04 crore in the corresponding period of last year. Its net sales also moved up by 15 per cent to Rs.383 crore from Rs.332 crore. Its sales of domestic formulations increased by 8 per cent to Rs.199 crore from Rs.184 crore and international generics sales up by 13 per cent to Rs.58 crore from Rs.52 crore in the same period of last year. It received approval for 2 ANDAs and it filed 3 DMFs during the third quarter.
For the nine months ended December 2011, its net sales increased by 24 per cent Rs.1,122 crore. Domestic sales went up by 13 per cent and exports up by 46 per cent. Profit before tax jumped by 43 per cent to Rs.134.05 crore against Rs.93.82 crore. Its net profit moved up by 46 per cent to Rs.109.83 crore from Rs.75.11 crore. The cumulative ANDA filings reached at 41 and it received approval for 17 products. Its cumulative DMF filings increased to 59 products. It has four brands viz., Azithral, Roxid, Althrocin and Wikoryl in the list of top 300 brands of the industry.
This is the first year of the company after the demerger becoming effective on April 1, 2011, the comparable figures for the corresponding quarter or nine months period of the previous financial year were not published. However, the numbers provided in the information memorandum filed with the stock exchanges after receiving order from High Court approving the scheme of demerger.